Endometrium neoplasm
Therapeutic area
Reproductive Health
Rare disease
No
- Definition
- A neoplasm (disease) that involves the endometrium.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Endometrium neoplasm
- Therapeutic area
- Reproductive Health
- endometrium neoplasm
- endometrial neoplasm
- endometrial tumor
- endometrial tumour
- endometrium neoplasm (disease)
- endometrium tumor
- endometrium tumour
- neoplasm of endometrium
- neoplasm of the endometrium
- tumor of endometrium
- tumor of the endometrium
- tumour of endometrium
- tumour of the endometrium
- Severity
- Severe
- Oncology
- Reproductive Health
Sources for recorded values
- MONDO ID
- MONDO:0021251
- Parent condition
- MONDO:0000931
Related records
Broader conditions (14)
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Endometrial disorder
- Female reproductive system disorder
- Female reproductive system neoplasm
- Human disease
- Neoplasm
- Neoplastic disease or syndrome
- Reproductive system disorder
- Reproductive system neoplasm
- Tumor of uterus
- Uterine disorder
Narrower conditions (27)
- Benign neoplasm of endometrium
- Endometrial adenosquamous carcinoma
- Endometrial cancer
- Endometrial carcinoma
- Endometrial clear cell adenocarcinoma
- Endometrial endometrioid adenocarcinoma with spindled epithelial cells
- Endometrial mixed adenocarcinoma
- Endometrial mucinous adenocarcinoma
- Endometrial small cell carcinoma
- Endometrial squamous cell carcinoma
- Endometrial stromal tumor
- Endometrial transitional cell carcinoma
- Endometrial undifferentiated carcinoma
- Endometrioid stromal sarcoma
- Endometrioid stromal sarcoma of the cervix
- Endometrioid stromal sarcoma of the vagina
- Endometrium adenocarcinoma
- Endometrium carcinoma in situ
- Fallopian tube endometrioid tumor
- Mucin-rich endometrial endometrioid adenocarcinoma
Trials (1,484)
- (VELA) Study of BLU-222 in Advanced Solid Tumors
- [F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers
- [SENTRY] Tailoring Postoperative Management Through Sentinel Lymph Node Biopsy in Low- and Intermediate-Risk Endometrial Cancer
- 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
- 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
- 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
- 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
- 27-Inch Versus 55-Inch Monitors in Women Undergoing Endometrial Cancer Surgery
- 2D Versus 3D Radical Laparoscopic Hysterectomy for Endometrial Cancer: a Prospective Randomized Trial
- 2D vs 3D Planning for High-Dose Rate (HDR) Gynecological Brachytherapy
- 3 Year Recurrence Free Survival in Ultra-low-risk Endometrial Cancer
- 3D Printed Custom Applicators for HDR BT (DISCO)
- 4FMFES-PET Imaging of Endometrial and Ovarian Cancers
- 68Ga-FAPI-PSMA PET Imaging for the Diagnosis of Solid Tumors
- 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
- A Beta-only IL-2 ImmunoTherapY Study
- A Biomarker Screening Protocol for Participants With Solid Tumors
- A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer
- A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
- A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
Approved drugs (2)
Drugs in development (19)
- Carboplatin Phase 3
- Cisplatin Phase 3
- Docetaxel Phase 3
- Doxorubicin Phase 3
- Durvalumab Phase 3
- Gedatolisib Phase 2
- Lenvatinib Phase 3
- Letrozole Phase 3
- Lodapolimab Phase 1
- LY-3321367 Phase 1
- Medroxyprogesterone acetate Phase 3
- Megestrol acetate Phase 3
- Niraparib Phase 2
- Olaparib Phase 3
- Paclitaxel Phase 3
- Pilaralisib Phase 2
- Sapanisertib Phase 2
- Serabelisib Phase 2
- Trastuzumab duocarmazine Phase 2